2rdt: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2rdt.jpg|left|200px]] | [[Image:2rdt.jpg|left|200px]] | ||
<!-- | |||
The line below this paragraph, containing "STRUCTURE_2rdt", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
| | --> | ||
| | {{STRUCTURE_2rdt| PDB=2rdt | SCENE= }} | ||
}} | |||
'''Crystal Structure of Human Glycolate Oxidase (GO) in Complex with CDST''' | '''Crystal Structure of Human Glycolate Oxidase (GO) in Complex with CDST''' | ||
| Line 23: | Line 20: | ||
==Reference== | ==Reference== | ||
Active Site and Loop 4 Movements within Human Glycolate Oxidase: Implications for Substrate Specificity and Drug Design., Murray MS, Holmes RP, Lowther WT, Biochemistry. 2008 Feb 26;47(8):2439-49. Epub 2008 Jan 24. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/18215067 18215067] | Active Site and Loop 4 Movements within Human Glycolate Oxidase: Implications for Substrate Specificity and Drug Design., Murray MS, Holmes RP, Lowther WT, Biochemistry. 2008 Feb 26;47(8):2439-49. Epub 2008 Jan 24. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/18215067 18215067] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
| Line 29: | Line 25: | ||
[[Category: Lowther, W T.]] | [[Category: Lowther, W T.]] | ||
[[Category: Murray, M S.]] | [[Category: Murray, M S.]] | ||
[[Category: | [[Category: Flavoprotein]] | ||
[[Category: | [[Category: Fmn]] | ||
[[Category: | [[Category: Glycolate pathway]] | ||
[[Category: | [[Category: Oxidoreductase]] | ||
[[Category: | [[Category: Peroxisome]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 16:42:42 2008'' | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | |||
Revision as of 16:42, 4 May 2008
Crystal Structure of Human Glycolate Oxidase (GO) in Complex with CDST
OverviewOverview
Human glycolate oxidase (GO) catalyzes the FMN-dependent oxidation of glycolate to glyoxylate and glyoxylate to oxalate, a key metabolite in kidney stone formation. We report herein the structures of recombinant GO complexed with sulfate, glyoxylate, and an inhibitor, 4-carboxy-5-dodecylsulfanyl-1,2,3-triazole (CDST), determined by X-ray crystallography. In contrast to most alpha-hydroxy acid oxidases including spinach glycolate oxidase, a loop region, known as loop 4, is completely visible when the GO active site contains a small ligand. The lack of electron density for this loop in the GO-CDST complex, which mimics a large substrate, suggests that a disordered to ordered transition may occur with the binding of substrates. The conformational flexibility of Trp110 appears to be responsible for enabling GO to react with alpha-hydroxy acids of various chain lengths. Moreover, the movement of Trp110 disrupts a hydrogen-bonding network between Trp110, Leu191, Tyr134, and Tyr208. This loss of interactions is the first indication that active site movements are directly linked to changes in the conformation of loop 4. The kinetic parameters for the oxidation of glycolate, glyoxylate, and 2-hydroxy octanoate indicate that the oxidation of glycolate to glyoxylate is the primary reaction catalyzed by GO, while the oxidation of glyoxylate to oxalate is most likely not relevant under normal conditions. However, drugs that exploit the unique structural features of GO may ultimately prove to be useful for decreasing glycolate and glyoxylate levels in primary hyperoxaluria type 1 patients who have the inability to convert peroxisomal glyoxylate to glycine.
About this StructureAbout this Structure
2RDT is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Active Site and Loop 4 Movements within Human Glycolate Oxidase: Implications for Substrate Specificity and Drug Design., Murray MS, Holmes RP, Lowther WT, Biochemistry. 2008 Feb 26;47(8):2439-49. Epub 2008 Jan 24. PMID:18215067 Page seeded by OCA on Sun May 4 16:42:42 2008